Type I interferons in anticancer immunity

Laurence Zitvogel; Lorenzo Galluzzi; Oliver Kepp; Mark J. Smyth; Guido Kroemer

doi:10.1038/nri3845

Type I interferons in anticancer immunity

Laurence Zitvogel, Lorenzo Galluzzi, Oliver Kepp, Mark J. Smyth, Guido Kroemer

Research output: Contribution to journal › Review article › peer-review

954 Scopus citations

Abstract

Type I interferons (IFNs) are known for their key role in antiviral immune responses. In this Review, we discuss accumulating evidence indicating that type I IFNs produced by malignant cells or tumour-infiltrating dendritic cells also control the autocrine or paracrine circuits that underlie cancer immunosurveillance. Many conventional chemotherapeutics, targeted anticancer agents, immunological adjuvants and oncolytic viruses are only fully efficient in the presence of intact type I IFN signalling. Moreover, the intratumoural expression levels of type I IFNs or of IFN-stimulated genes correlate with favourable disease outcome in several cohorts of patients with cancer. Finally, new anticancer immunotherapies are being developed that are based on recombinant type I IFNs, type I IFN-encoding vectors and type I IFN-expressing cells.

Original language	English
Pages (from-to)	405-414
Number of pages	10
Journal	Nature Reviews Immunology
Volume	15
Issue number	7
DOIs	https://doi.org/10.1038/nri3845
State	Published - Jul 26 2015
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/nri3845

Cite this

@article{a5b07d27405e45dd8a72cf07a6ed30e0,

title = "Type I interferons in anticancer immunity",

abstract = "Type I interferons (IFNs) are known for their key role in antiviral immune responses. In this Review, we discuss accumulating evidence indicating that type I IFNs produced by malignant cells or tumour-infiltrating dendritic cells also control the autocrine or paracrine circuits that underlie cancer immunosurveillance. Many conventional chemotherapeutics, targeted anticancer agents, immunological adjuvants and oncolytic viruses are only fully efficient in the presence of intact type I IFN signalling. Moreover, the intratumoural expression levels of type I IFNs or of IFN-stimulated genes correlate with favourable disease outcome in several cohorts of patients with cancer. Finally, new anticancer immunotherapies are being developed that are based on recombinant type I IFNs, type I IFN-encoding vectors and type I IFN-expressing cells.",

author = "Laurence Zitvogel and Lorenzo Galluzzi and Oliver Kepp and Smyth, {Mark J.} and Guido Kroemer",

note = "Publisher Copyright: {\textcopyright} 2015 Macmillan Publishers Limited.",

year = "2015",

month = jul,

day = "26",

doi = "10.1038/nri3845",

language = "English",

volume = "15",

pages = "405--414",

journal = "Nature Reviews Immunology",

issn = "1474-1733",

publisher = "Nature Publishing Group",

number = "7",

}

TY - JOUR

T1 - Type I interferons in anticancer immunity

AU - Zitvogel, Laurence

AU - Galluzzi, Lorenzo

AU - Kepp, Oliver

AU - Smyth, Mark J.

AU - Kroemer, Guido

PY - 2015/7/26

Y1 - 2015/7/26

N2 - Type I interferons (IFNs) are known for their key role in antiviral immune responses. In this Review, we discuss accumulating evidence indicating that type I IFNs produced by malignant cells or tumour-infiltrating dendritic cells also control the autocrine or paracrine circuits that underlie cancer immunosurveillance. Many conventional chemotherapeutics, targeted anticancer agents, immunological adjuvants and oncolytic viruses are only fully efficient in the presence of intact type I IFN signalling. Moreover, the intratumoural expression levels of type I IFNs or of IFN-stimulated genes correlate with favourable disease outcome in several cohorts of patients with cancer. Finally, new anticancer immunotherapies are being developed that are based on recombinant type I IFNs, type I IFN-encoding vectors and type I IFN-expressing cells.

AB - Type I interferons (IFNs) are known for their key role in antiviral immune responses. In this Review, we discuss accumulating evidence indicating that type I IFNs produced by malignant cells or tumour-infiltrating dendritic cells also control the autocrine or paracrine circuits that underlie cancer immunosurveillance. Many conventional chemotherapeutics, targeted anticancer agents, immunological adjuvants and oncolytic viruses are only fully efficient in the presence of intact type I IFN signalling. Moreover, the intratumoural expression levels of type I IFNs or of IFN-stimulated genes correlate with favourable disease outcome in several cohorts of patients with cancer. Finally, new anticancer immunotherapies are being developed that are based on recombinant type I IFNs, type I IFN-encoding vectors and type I IFN-expressing cells.

UR - http://www.scopus.com/inward/record.url?scp=84933277745&partnerID=8YFLogxK

U2 - 10.1038/nri3845

DO - 10.1038/nri3845

M3 - Review article

C2 - 26027717

AN - SCOPUS:84933277745

SN - 1474-1733

VL - 15

SP - 405

EP - 414

JO - Nature Reviews Immunology

JF - Nature Reviews Immunology

IS - 7

ER -

Type I interferons in anticancer immunity

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this